Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other financing activities (2018 - 2025)

Iovance Biotherapeutics has reported Other financing activities over the past 5 years, most recently at -$445000.0 for Q4 2025.

  • Quarterly results put Other financing activities at -$445000.0 for Q4 2025, up 49.43% from a year ago — trailing twelve months through Dec 2025 was -$7.1 million (up 45.12% YoY), and the annual figure for FY2025 was -$7.1 million, up 45.1%.
  • Other financing activities for Q4 2025 was -$445000.0 at Iovance Biotherapeutics, up from -$464000.0 in the prior quarter.
  • Over the last five years, Other financing activities for IOVA hit a ceiling of -$186000.0 in Q4 2023 and a floor of -$6.3 million in Q3 2024.
  • Median Other financing activities over the past 3 years was -$692000.0 (2024), compared with a mean of -$1.9 million.
  • Biggest five-year swings in Other financing activities: tumbled 1556.2% in 2024 and later surged 92.61% in 2025.
  • Iovance Biotherapeutics' Other financing activities stood at -$186000.0 in 2023, then plummeted by 373.12% to -$880000.0 in 2024, then surged by 49.43% to -$445000.0 in 2025.
  • The last three reported values for Other financing activities were -$445000.0 (Q4 2025), -$464000.0 (Q3 2025), and -$504000.0 (Q2 2025) per Business Quant data.